Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2010

View Archived Issues

NicOx's NO-donating agents show preclinical promise in ophthalmology and pain

Serum bilirubin modulates response to bucindolol in patients with heart failure

Potent inhibitors identified of GIST-relevant kinases

Merck & Co. claims new cholesterol absorption inhibitors

Merck & Co. presents new sst5 receptor antagonists

NeuroSearch discovers new monoamine reuptake inhibitors

GlaxoSmithKline presents new AMPA receptor agonists

TransTech and Forest enter into agreement to develop GKAs

Vivalis and Sanofi Pasteur join to discover MAbs for infectious diseases

Nautilus Neurosciences launches Cambia for migraine in the U.S.

Simvastatin/ezetimibe combination promotes tumor growth in prostate cancer model

QBI-139 enters phase I trial in advanced/refractory solid tumors

Inhaled formoterol fumarate/glycopyrrolate is safe in healthy subjects

Protalix BioTherapeutics completes phase I trial of PRX-105

European Commission extends indication of RoActemra

Phase II data reported on IFN alpha-2b in patients with anogenital warts

Discovery receives FDA guidance for preclinical Surfaxin program in neonatal RDS

Idera reports preliminary phase I data on IMO-3100

Nektar Therapeutics reports phase II data on NKTR-102 in breast cancer

Aerovance presents phase IIb data on pitrakinra in eosinophilic asthma

NanoViricides' anti-HIV candidates efficacious against two HIV-1 isolates in vitro

Columbia Labs completes enrollment in phase III Prochieve trial

Eisai and Helsinn enter license agreement for antiemetic combination agent

Engrailed-2 proposed as diagnostic biomarker for prostate cancer

Phase III lubiprostone trial in idiopathic constipation complete

Eisai presents the year's product and financial highlights

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...